Search International and National Patent Collections
Refine Search
Query Tree
Save query
A private query is only visible to you when you are logged-in and can not be used in RSS feeds
Results 1-10 of 1,721 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 173
Analysis
List Length
TitleCtrPubDate
Appl.NoApplicantInventorInt.Class
Means for treating inflammatory diseases, autoimmune diseases and cancer
EP12.11.2008
07009444FRAUNHOFER GES FORSCHUNGHORN FRIEDEMANN
C12N 15/113
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
This invention relates to a compound, wherein said compound is (a) a polynucleotide comprising or consisting of a base sequence of contiguous bases from the sequence of any one of SEQ ID NOs: 1 to 5, said base sequence being at least 15 bases in length; (b) a polynucleotide having at least 80% sequence identity to the polynucleotide of (a) over the entire length of said base sequence; (c) an analog or derivative of (a) or (b); or (d) a polynucleotide or analog or derivative thereof which is complementary to the full length of any one of (a) to (c); wherein said polynucleotide having at least 80% sequence identity, said analog, or said derivative is capable of interacting with a nucleic acid comprising a double-stranded part, said part comprising the sequence of any one of SEQ ID NOs: 1 to 5. The sequences of SEQ ID NOs: 1 to 5 define the Stat3-binding region of the gene encoding the micro RNA miR-21 and homologues thereof.

METHOD FOR PRODUCTION OF 1,5-DIDEOXY-1,5-IMINO HEXITOL FROM OXIME OR IMINE
JP10.01.2008
2007200331UNIV MICHIGAN STATEHOLLINGSWORTH RAWLE I
C07B 61/00
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
B
GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
61
Other general methods
PROBLEM TO BE SOLVED: To provide a method for preparation of 1,5-dideoxy-1,5-imino hexitols of hexose sugars from new hydroxy group-protected oxime intermediates.

SOLUTION: The method includes the processes of (a) reacting an acid ester or a hydrazide of a 5-hexulosonic acid oxime or alkylimine with hydrogen and a hydrogenation catalyst in an acidic solvent to form a 5-imino-5-deoxyaldonic acid lactam and (b) reducing the lactam with a reducing agent to form the 1,5-dideoxy-1,5-imino hexitol. The hexitols are useful as drugs.

COPYRIGHT: (C)2008,JPO&INPIT


SUGAR ALCOHOL ESTER OR ETHER, CHOLESTERIC LIQUID CRYSTAL ADDITIVE, LIQUID CRYSTAL COMPOSITION AND DISPLAY ELEMENT
JP18.12.2008
2008086903独立行政法人産業技術総合研究所秋山 陽久
C09K 19/54
C CHEMISTRY; METALLURGY
09
DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
K
MATERIALS FOR APPLICATIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
19
Liquid crystal materials
52
characterised by components which are not liquid crystals, e.g. additives
54
Additives having no specific mesophase
PROBLEM TO BE SOLVED: To provide a new additive to be added to a cholesteric liquid crystal and to obtain a liquid crystal display element produced by the addition of the additive.

SOLUTION: The new sugar alcohol ester or ether is represented by general formula (1) [wherein R is a group represented by general formula (2) (wherein A is an aliphatic group; B and C are each a group selected from an ester, an ether and a methylene group or A-B- is a group selected from a hydrogen group or a methyl group; D is a bifunctional saturated hydrocarbon group; E is a group selected from a carbonyl group, a methylene group and an oxycarbonyl ethylene carbonyl group; and n is an integer of 1-6)]. The liquid crystal composition and the display element each comprises the same.

COPYRIGHT: (C)2009,JPO&INPIT


Methods For Identifying Compounds Capable of Modulating the Hydrolase Activity of Clca Protein
US25.09.2008
10590691LEPISTO MATTILepisto Matti
C12Q 1/34
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
34
involving hydrolase

Methods for identifying compounds capable of modulating the hydrolase activity of a CLCA protein include screening and computer modelling methods. The compounds, including antibodies, may be useful as therapeutic agents to treat a variety of diseases.


生分解性樹脂組成物、その製造方法、およびそれを用いた成形体
JP24.01.2008
JP2007000769ユニチカ株式会社川原 光博
C08L 101/16
C CHEMISTRY; METALLURGY
08
ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
L
COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
101
Compositions of unspecified macromolecular compounds
16
the macromolecular compounds being biodegradable

生分解性樹脂組成物であって、α−および/またはβ−ヒドロキシカルボン酸単位とω−ヒドロキシアルカノエート単位とのいずれかを主成分とする生分解性ポリエステル樹脂と、層状珪酸塩と、糖アルコールの脱水縮合物と脂肪酸とからなる脂肪酸エステルとを含有する。この生分解性樹脂組成物は、耐熱性があるとともに、透明性が高く凝集物の少ない、すなわち良好な外観を維持したものである。


PROCESS FOR THE PRODUCTION OF ANHYDROSUGAR ALCOHOLS
EP10.12.2008
07752855ARCHER DANIELS MIDLAND COSANBORN ALEXANDRA J
C07D 493/06
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
493
Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
02
in which the condensed system contains two hetero rings
06
Peri-condensed systems
A process is provided for the preparation of anhydrosugar alcohols. The process involves heating a sugar alcohol or a monoanhydrosugar alcohol starting material in the presence of an acid catalyst and under pressure. Optionally the resulting product is purified. Very high purities are achieved, without necessitating the use of organic solvents in the process.

Method For Assessing the Predisposition and/or Susceptibility to Copd by Analysing Fgf-Bp1
US10.07.2008
11910092ASTRAZENECA ABKoopmann Witte
A61K 31/519
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings

The present invention relates to the discovery of an association between the gene encoding FGF-BP1 (fibroblast growth factor-binding protein) and chronic obstructive pulmonary disease (COPD). The invention identifies a role for FGF-BP1 in COPD. The present invention therefore relates to diagnostic techniques for the detection of COPD by detecting all or part of this gene, its precursors or products (mRNA, cDNA, genomic DNA, or protein). The present invention also provides methods and as-says for identifying compounds which modulate FGF-BP1 and which may be used for treating respiratory diseases such as COPD. Furthermore, the invention relates to polymorphisms in the genes encoding FGF-BP1. The invention also relates to the use of polymorphisms in the FGF-BP1-encoding genes in assessing predisposition and/or susceptibility of an individual to chronic obstructive pulmonary disease (COPD).


Modified Nucleosides for Rna Interference
US23.10.2008
11718793K.U. LEUVEN RESEARCH AND DEVELOPMENTHerdewijn Piet
A61K 31/70
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof

The present invention relates to the use of modified nucleotides and single or double stranded oligonucleotides having at least one of said modified nucleotides for performing RNA interference. The modified nucleotides are selected from 6-membered ring containing nucleotides such as hexitol, altritol, O-substituted or O-alkylated altritol, cyclohexenyl, ribo-cyclohexenyl and O-substituted or O-alkylated ribo-cyclohexenyl nucleotides. The present invention also relates to novel modified nucleosides or nucleotides and to the use of the novel modified nucleosides and nucleotides in single or double stranded oligonucleotides for RNA interference, antisense therapy or other applications.


Methods and compositions relating to CCR5 antagonist, IFN-γ and IL-13 induced inflammation
US08.05.2008
10582610Yale UniversityMa Bing
A61K 39/395
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

The present invention includes compositions and methods for the treatment of Th1 and/or Th2 medicated inflammatory diseases, relating to inhibiting CCR5. This is because the present invention demonstrates, for the first time, that expression of IFN-γ, IL-13, and CCR5 mediates and/or is associated with Th1 and/or Th2 inflammatory diseases and that inhibiting CCR5 treats, and even prevents, the diseases. Thus, the Invention relates to the novel discovery that inhibiting CCR5 treats and prevents Th1 and/or Th2 mediated inflammatory disease.


Method for preparing dianhydrohexitol diester compositions
CN02.04.2008
200680011195.3Roquette FreresFuertes Patrick
C07D 493/04
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
493
Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
The invention concerns a method for preparing a dianhydrohexitol diester composition, characterized in that it comprises a step which consists in esterifying a dianhydrohexitol composition with a carboxylic acid in the presence of an acid catalyst and hypophosphorous acid. Preferably, the hypophosphorous acid is introduced in an amount ranging between 0.05 and 2 wt. % of dianhydrohexitol, and in a hypophosphorous acid/acid catalyst weight ratio less than 1/1. Said method enables novel dianhydrohexitol diester compositions, for example isosorbide diesters, isomannide and/or isoidide richer in diester(s) and/or less coloured, useful in numerous industrial applications, in particular in plastic compositions, to be obtained.

Results 1-10 of 1,721 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 173